Clinical Trial Update: Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating trifluridine/tipiracil in combination with irinotecan as second-line therapy for cholangiocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Irinotecan (Irinotecan)
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED